U.S., July 26 -- ClinicalTrials.gov registry received information related to the study (NCT07085962) titled 'Efficacy and Safety of Calculus Bovis Sativus in Adults With MAFLD' on June 12.
Brief Summary: Metabolic dysfunction-associated fatty liver disease (MAFLD) has become the most common chronic liver disease worldwide. Timely therapeutic intervention for MAFLD is crucial for improving patient prognosis and preventing its progression to liver fibrosis, cirrhosis, and even hepatocellular carcinoma (HCC). Therefore, the discovery of novel drugs for the treatment of MAFLD is of great significance.
Previous clinical studies have shown that calculus bovis sativus, as an adjuvant therapy for icteric hepatitis and chronic hepatitis B, exhibit...